These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19567303)

  • 1. Re: B.J. De Castro and K. C. Baker: Effect of flexible cystoscopy on serum prostate-specific antigen values (Urology 2009; 73:237-240).
    Romics I
    Urology; 2009 Jul; 74(1):234. PubMed ID: 19567303
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: De Castro et al.: Effect of flexible cystoscopy on serum prostate-specific antigen values. (Urology 2009;73:237-240).
    Madersbacher S
    Urology; 2009 Jun; 73(6):1428. PubMed ID: 19482171
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
    Stamatiou K; Alevizos A; Mariolis A; Sofras F
    J Urol; 2006 Sep; 176(3):1251-2; author reply 1252. PubMed ID: 16890735
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Management of lower urinary tract symptoms secondary to benign prostatic hyperplasia with open prostatectomy: results of a contemporary series. B. Helfand, S. Mouli, R. Dedhia and K. T. McVary, J Urol 2006; 176: 2557-2561.
    Dutkiewicz SA
    J Urol; 2007 Jun; 177(6):2398-9; author reply 2399. PubMed ID: 17509372
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. S. E. Eggener, K. A. Roehl, O. Yossepowitch and W. J. Catalona, J Urol 2006; 176: 1399-1403.
    Wagner MD; Daneshmand S; Sokoloff M; Barry JM
    J Urol; 2007 Jun; 177(6):2396; author reply 2396-7. PubMed ID: 17509368
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy.
    Elmansy HM; Elzayat EA; Sampalis JS; Elhilali MM
    Urology; 2009 Nov; 74(5):1105-10. PubMed ID: 19773035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer: I. M. Thompson, D. P. Ankerst, R. Etzioni and T. Wang J Urol 2008; 180: 1219-1222.
    Walsh PC
    J Urol; 2009 Mar; 181(3):1499; author reply 1499-500. PubMed ID: 19157429
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: The effect of digital rectal examination, flexible cystoscopy and prostatic biopsy on free and total prostate specific antigen, and the free-to-total prostate specific antigen ratio in clinical practice.
    Riedl CR; Pflüger H
    J Urol; 1998 Apr; 159(4):1313. PubMed ID: 9507873
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Prostate specific antigen: a decade of discovery--what we have learned and where we are going.
    Scholz MC; Strum SB
    J Urol; 2000 Apr; 163(4):1259-60. PubMed ID: 10737522
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor: B. I. Rini, L. Fong, v. Weinberg, B. Kavanaugh and E. J. Small. J Urol 2006; 175: 2087-2091.
    Brú A
    J Urol; 2007 Apr; 177(4):1585; author reply 1585-6. PubMed ID: 17382784
    [No Abstract]   [Full Text] [Related]  

  • 11. [Urology].
    Jichlinski P; Wisard M
    Rev Med Suisse; 2009 Jan; 5(186):144-6. PubMed ID: 19238935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial comment.
    Carter HB
    Urology; 2009 Jul; 74(1):183; aurhor reply 183-4. PubMed ID: 19567300
    [No Abstract]   [Full Text] [Related]  

  • 13. What would you do, doctor?
    Smith JA
    J Urol; 2009 Aug; 182(2):421-2. PubMed ID: 19524982
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Singh A
    Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
    [No Abstract]   [Full Text] [Related]  

  • 15. Changes in serum prostate-specific antigen levels.
    Keller DL
    Mayo Clin Proc; 2012 Oct; 87(10):1033; author reply 1033. PubMed ID: 23036676
    [No Abstract]   [Full Text] [Related]  

  • 16. Epidemiological association between C-reactive protein and prostate-specific antigen.
    Lippi G; Montagnana M; Guidi GC
    Cancer; 2009 Mar; 115(5):1132. PubMed ID: 19156910
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: The 20-core prostate biopsy protocol--a new gold standard?: V. Ravery, S. Dominique, X. Panhard, M. Toublanc, L. Boccon-Gibod and L. Boccon-Gibod. J Urol 2008; 179: 504-507.
    Serefoglu EC; Ozdemir AT; Balbay MD
    J Urol; 2008 Nov; 180(5):2256-7. PubMed ID: 18804806
    [No Abstract]   [Full Text] [Related]  

  • 18. Hemodilution of prostate-specific antigen levels among obese men.
    Rundle A; Richards C; Neugut AI
    Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2343; author reply 2343-4. PubMed ID: 19661096
    [No Abstract]   [Full Text] [Related]  

  • 19. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men.
    Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M
    Urol J; 2009; 6(3):182-8. PubMed ID: 19711272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weighing the benefits and downsides of prostate-specific antigen screening.
    Pignone M
    Arch Intern Med; 2009 Sep; 169(17):1554-6. PubMed ID: 19786672
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.